Atomo Diagnostics Ltd Cash Flow Conversion Efficiency
Atomo Diagnostics Ltd cash flow conversion efficiency. Based on the latest financial reports, Atomo Diagnostics Ltd (AT1) has a cash flow conversion efficiency ratio of -0.145x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-962.50K ≈ $-681.03K USD) by net assets (AU$6.64 Million ≈ $4.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Atomo Diagnostics Ltd (2017–2025)
Cash flow conversion efficiency of Atomo Diagnostics Ltd from 2017 to 2025. This chart illustrates how Atomo Diagnostics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Atomo Diagnostics Ltd (AT1) stock price for real-time trading data and today's change.
Atomo Diagnostics Ltd Cash Flow Conversion Ratio Explained
Atomo Diagnostics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Atomo Diagnostics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atomo Diagnostics Ltd ranked by their cash flow conversion efficiency. Also see how much is Atomo Diagnostics Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nakoda Group of Industries Limited
NSE:NGIL
|
-0.035x |
|
Mont Royal Resources Ltd
AU:MRZ
|
-0.018x |
|
Yorkton Equity Group Inc
V:YEG
|
0.071x |
|
HYDROGEN UTOPIA INT.-001
F:D60
|
N/A |
|
IP Group
LSE:IPO
|
-0.002x |
|
Workspace Group PLC
LSE:WKP
|
0.018x |
|
Trinseo SA
NYSE:TSE
|
0.258x |
|
Willamette Valley Vineyards Inc
NASDAQ:WVVI
|
0.029x |
Annual Cash Flow Conversion Efficiency for Atomo Diagnostics Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Atomo Diagnostics Ltd from 2017 to 2025. Review Atomo Diagnostics Ltd (AT1) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$6.98 Million ≈ $4.94 Million |
AU$-1.96 Million ≈ $-1.39 Million |
-0.281x | +39.57% |
| 2024-06-30 | AU$10.08 Million ≈ $7.14 Million |
AU$-4.69 Million ≈ $-3.32 Million |
-0.465x | -17.53% |
| 2023-06-30 | AU$14.79 Million ≈ $10.47 Million |
AU$-5.85 Million ≈ $-4.14 Million |
-0.395x | -249.55% |
| 2022-06-30 | AU$24.81 Million ≈ $17.56 Million |
AU$-2.81 Million ≈ $-1.99 Million |
-0.113x | +19.46% |
| 2021-06-30 | AU$30.09 Million ≈ $21.29 Million |
AU$-4.23 Million ≈ $-2.99 Million |
-0.140x | +22.67% |
| 2020-06-30 | AU$34.48 Million ≈ $24.40 Million |
AU$-6.26 Million ≈ $-4.43 Million |
-0.182x | -154.05% |
| 2019-06-30 | AU$-5.47 Million ≈ $-3.87 Million |
AU$-1.84 Million ≈ $-1.30 Million |
0.336x | -70.46% |
| 2018-06-30 | AU$-4.89 Million ≈ $-3.46 Million |
AU$-5.56 Million ≈ $-3.93 Million |
1.137x | +101.03% |
| 2017-06-30 | AU$47.82K ≈ $33.83K |
AU$-5.26 Million ≈ $-3.72 Million |
-109.899x | -- |
About Atomo Diagnostics Ltd
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.